Form 4: Edwards Lifesciences Executive Daniel J. Lippis Reports Stock Transactions

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports the acquisition and disposal of common stock and the exercise of employee stock options on March 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 10, 2025, Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reported transactions involving the company's common stock.
• Lippis acquired 400 shares of common stock through the exercise of employee stock options at a price of $45.2767 per share.
• Simultaneously, Lippis disposed of 400 shares of common stock at a price of $69.48 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 11, 2023.
• Following these transactions, Lippis beneficially owns 22,588.0651 shares of Edwards Lifesciences common stock.
• Lippis also holds options to acquire 630 shares of common stock at an exercise price of $45.2767.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports routine stock transactions by an executive under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to stock transactions.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their trading activities. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive stock transactions are common across publicly traded companies like Edwards Lifesciences.
• The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of insider trading, similar to plans used by executives at Medtronic, Boston Scientific, and Abbott.
• The reported transactions are typical in terms of volume and price range compared to other executive stock transactions in the medical device industry.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the stock's trading volume.

Key Dates